Jan 02nd 2013 - Edison Investment Research today published a report on Evolva entitled "Rejuvenation Ahead Of Key Time". In summary, the report says:
Evolva has expanded its pipeline with the acquisition of a yeast-based resveratrol programme from the distressed Danish company Fluxome. The purchase is opportunistic and should become cash flow enhancing in 2014. However, Evolva’s other assets are still the main value drivers. This may be highlighted in H113 by the potential partnering of the stevia and vanilla programmes, which could generate significant revenues and validate Evolva’s strategy. We have increased our valuation by CHF54m to CHF269m, CHF1.52 per share.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »